Want to see SE:IVACC full AI Analyst Report?
Top Page
Intervacc AB
(IVACC)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr1.00
▼(-4.76% Downside)
Action:Reiterated
Date:08/21/26
The score is primarily constrained by weak financial performance—persistent losses, negative gross profit, and ongoing free-cash-flow burn—despite a low-debt balance sheet. Technicals add only modest support as oversold indicators contrast with a still-weak trend, while valuation remains unattractive due to loss-making earnings and no dividend support.
Positive Factors
Low Financial Leverage
Near-zero leverage limits interest and refinancing risk, preserving financial flexibility while the company funds research, commercialization, and market expansion in a capital-intensive biotech model.
Negative Factors
Persistent Unprofitability
Sustained losses and negative gross profit show that current pricing, scale, or production economics are insufficient to support the business, weakening internal funding capacity and making a durable path to profitability uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Near-zero leverage limits interest and refinancing risk, preserving financial flexibility while the company funds research, commercialization, and market expansion in a capital-intensive biotech model.
Read all positive factors
Intervacc AB (IVACC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr378.30M
Dividend YieldN/A
Average Volume (3M)298.77K
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue Growth-0.71%
EPS Growth54.16%
CountrySE
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume227,239
30 Day Avg. Volume298,770
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)kr21.60M
Intervacc AB Business Overview & Revenue Model
Company Description
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, includin...
How the Company Makes Money
Intervacc makes money primarily by selling its veterinary vaccine product(s). Revenue is generated through commercialization of its marketed canine vaccine (sold to veterinary clinics and animal health distributors/wholesalers, depending on market...
Intervacc AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.11M | 20.09M | 11.79M | 8.02M | 9.68M | 5.24M |
| Gross Profit | -71.88M | -67.41M | -3.53M | -13.81M | 3.37M | 6.25M |
| EBITDA | -76.15M | -66.25M | -58.75M | -68.98M | -57.73M | -23.15M |
| Net Income | -91.75M | -80.81M | -75.52M | -102.85M | -64.16M | -29.38M |
Balance Sheet | ||||||
| Total Assets | 266.68M | 294.43M | 187.32M | 259.61M | 265.04M | 329.39M |
| Cash, Cash Equivalents and Short-Term Investments | 127.64M | 160.89M | 34.40M | 88.34M | 45.70M | 115.71M |
| Total Debt | 866.00K | 108.00K | 145.00K | 181.00K | 322.00K | 433.00K |
| Total Liabilities | 33.62M | 19.52M | 24.99M | 21.68M | 14.88M | 21.14M |
| Stockholders Equity | 233.06M | 274.91M | 162.33M | 237.93M | 250.16M | 308.25M |
Cash Flow | ||||||
| Free Cash Flow | -67.48M | -66.92M | -53.90M | -47.94M | -75.92M | -48.67M |
| Operating Cash Flow | -65.64M | -65.79M | -53.20M | -45.83M | -69.79M | -25.46M |
| Investing Cash Flow | -9.59M | -1.13M | -706.00K | -2.11M | -6.13M | -23.13M |
| Financing Cash Flow | 818.00K | 193.40M | -36.00K | 90.58M | 5.91M | 50.00K |
Intervacc AB Technical Analysis
Neutral
1.05
Price Trends
1.21
Negative
1.22
Negative
1.03
Positive
Market Momentum
-0.03
Negative
44.64
Neutral
76.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IVACC, the sentiment is Neutral. The current price of 1.05 is below the 20-day moving average (MA) of 1.13, below the 50-day MA of 1.21, and above the 200-day MA of 1.03, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 44.64 is Neutral, neither overbought nor oversold. The STOCH value of 76.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:IVACC.
Intervacc AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr497.63M | 2.60 | 63.09% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr466.87M | -4.11 | -18.05% | ― | ― | 15.97% | |
46 Neutral | kr378.30M | -4.19 | -34.25% | ― | -0.71% | 54.16% | |
43 Neutral | kr1.60B | -3.22 | -99.58% | ― | -87.22% | -70.29% | |
41 Neutral | kr31.94M | -0.20 | -104.71% | ― | -2.29% | 55.71% | |
40 Underperform | kr172.73M | -0.02 | -736.08% | ― | -98.81% | 80.33% |
* Healthcare Sector Average
SE:IVACC
Intervacc AB
1.11
-0.05
-4.48%
SE:ATORX
Alligator Bioscience AB
0.03
-0.91
-97.32%
SE:BINV
BioInvent International AB
24.30
-5.10
-17.35%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
1.35
-6.55
-82.96%
SE:IMMU
Immunicum AB
7.36
0.46
6.67%
SE:CANTA
Cantargia AB
1.77
-0.83
-31.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.